Sargramostim
Also known as: CSL795, GM-CSF, Leukine, Molgramostim, rhu GM-CSF, rhuGM‑CSF, SAR
Source Sargramostim at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Affiliate link: we earn a commission on purchases made through this link, at no extra cost to you.
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Sargramostim is a prescription‑only, recombinant human granulocyte‑macrophage colony‑stimulating factor (GM‑CSF) belonging to the colony‑stimulating factor family. It is administered by injection (intravenous or subcutaneous) and, in an inhaled formulation, directly to the lungs. The protein stimulates myeloid cells and is being explored as an immune adjuvant in cancer vaccines, as a synergist with checkpoint inhibitors for melanoma, and as a disease‑modifying therapy for autoimmune pulmonary alveolar proteinosis (aPAP).
Mechanism of Action
Sargramostim mimics endogenous GM‑CSF and binds the GM‑CSF receptor on hematopoietic progenitors, mature granulocytes, macrophages and dendritic cells. This engagement promotes cell survival, proliferation, and functional activation, enhancing antigen presentation and cytokine release. By bolstering innate immune cells, sargramostim indirectly supports adaptive responses such as T‑cell activation, which underlies its use as an immunologic adjuvant and as a means to restore alveolar macrophage function in aPAP.
What the Research Shows
A phase IIa open‑label trial in newly diagnosed glioblastoma combined subcutaneous sargramostim with a survivin‑targeted peptide vaccine (SurVaxM) and temozolomide. The regimen was well tolerated, generated survivin‑specific CD8+ T‑cells, and yielded a median overall survival of 25.9 months among 63 evaluable patients. A 2021 review highlighted pre‑clinical and early clinical evidence that sargramostim can augment checkpoint‑inhibitor activity in metastatic melanoma, potentially improving efficacy and reducing immune‑related toxicity. In a 2024 randomized study of 18 patients with moderate‑to‑severe aPAP, inhaled sargramostim after whole‑lung lavage extended the time to rescue lavage (30 vs 18 months), improved oxygenation, diffusing capacity, and disease biomarkers, with no serious adverse events reported.
Reported Benefits
Clinical data suggest sargramostim can reduce the need for repeat whole‑lung lavage and improve lung function in aPAP patients. In glioblastoma, the addition of sargramostim to a peptide vaccine was associated with durable immune responses and prolonged survival compared with historical expectations. Preliminary melanoma studies propose that sargramostim may enhance checkpoint‑inhibitor efficacy and mitigate related toxicities, though definitive outcome data are pending.
Limitations of the Evidence
Evidence for cancer indications remains limited to small, non‑randomized or early‑phase studies; the glioblastoma trial lacked a control arm, and the melanoma literature is a narrative review without new trial results. The aPAP trial, while randomized, enrolled only 18 participants, limiting generalizability. Long‑term safety and optimal dosing regimens have not been established across indications, and larger confirmatory trials are required.
Safety Considerations
Across the cited studies, sargramostim was generally well tolerated. No serious adverse events were attributed to the drug in the glioblastoma or aPAP trials, and only mild injection‑site reactions, fever, or bone pain are commonly reported with GM‑CSF therapies. Caution is advised in patients with known hypersensitivity to yeast‑derived proteins, active infections, or uncontrolled inflammatory conditions. Monitoring for pulmonary symptoms is prudent when using inhaled formulations.
How It Is Administered
Sargramostim is supplied as a sterile protein solution for intravenous or subcutaneous injection; dosing schedules vary by clinical protocol. An inhaled aerosol formulation has been investigated for aPAP, delivered via nebulizer after whole‑lung lavage. The drug is prescription‑only and administered by healthcare professionals under monitored conditions.
Routes of Administration
Goals & Uses
- Treatment of acute radiation syndrome (ARS)Radiation Emergency CountermeasureModerate
- Neutrophil recovery in AML induction chemotherapyOncology Supportive CareHigh
- Accelerate neutrophil recoveryHematologyHigh
- Graft failure or engraftment delayHematopoietic SupportModerate
- Treat pulmonary alveolar proteinosisRespiratoryModerate
- Mobilization of hematopoietic progenitor cellsHematologyHigh
- Accelerate myeloid recovery after bone marrow transplantationHematopoietic SupportHigh
- Immunomodulation in COVID-19 (investigational)ImmunotherapyLow
Contraindications
- Hypersensitivity to sargramostim or yeast proteinsAllergyModerate
- Hypersensitivity to sargramostim, yeast-derived products, or any componentAllergyHigh
- Active systemic infection without adequate antimicrobial coverageInfectionModerate
- Neonates (benzyl alcohol-containing formulation)PediatricHigh
- Concurrent use with chemotherapy or radiotherapyOncologyHigh
- Excessive leukemic myeloid blasts in bone marrow or peripheral blood (≥10%)OncologyHigh
Adverse Effects
- Bone painMusculoskeletalCommon
- Fever and constitutional symptomsGeneralCommon
- Fluid retention / peripheral edemaCardiovascularUncommon
- Injection site reactionsLocalCommon
- Capillary leak syndromeVascularRareLeakage of fluid from blood vessels into tissues
- First-dose reaction (flushing, hypotension, tachycardia, dyspnea)HypersensitivityUncommon
- FeverSystemicCommonElevated body temperature
- Injection site reactionLocalCommonRedness, swelling, itching, bruising, or pain at the injection site
Drug Interactions
- Cytotoxic chemotherapy agentsHigh
- WarfarinModerate
- Cytotoxic chemotherapyLow
- CorticosteroidsModerate
- LithiumLow
Population Constraints
- PregnancyReproductive SafetyRelative
- Neonates / premature infants (benzyl alcohol formulation)PediatricAbsolute
- Patients with pre-existing pulmonary diseaseRespiratoryRelative
- Patients with pre-existing cardiac diseaseCardiovascularRelative
- Pediatrics (<2 years)AgeRelative
- Renal or hepatic impairmentOrgan DysfunctionRelative
Regulatory Status
- European UnionApprovedApproved: Myeloid recovery, Pulmonary alveolar proteinosis (inhaled)Inhaled sargramostim (Leukine® Inhalation) approved for PAP.
- United StatesApprovedApproved: Myeloid recovery after bone‑marrow transplant, Acute myeloid leukemia, Infection prophylaxis in neutropenic patientsSubcutaneous or intravenous; inhaled formulation not FDA‑approved.
- United KingdomApprovedApproved: Myeloid recovery, Acute myeloid leukemiaSame indications as US; inhaled use off‑label.
FDA‑approved (US) for myeloid recovery post‑bone‑marrow transplant, for acute myeloid leukemia, and for infection prophylaxis; EMA‑approved (EU) for similar indications and for pulmonary alveolar proteinosis (inhaled formulation).
Evidence & Sources
- Journal ArticleModerateAhluwalia MS, et al.2023-01-01T00:00:00.000000Z
- Journal ArticleModerateTarhini AA, Joshi I, Garner F2021-01-01T00:00:00.000000Z
- Journal ArticleModerateCampo I, et al.2024-01-01T00:00:00.000000Z
Frequently Asked Questions
What therapeutic areas is sargramostim currently being studied for?
Beyond its approved use to support bone‑marrow recovery, sargramostim is being evaluated as an immune adjuvant in glioblastoma vaccine trials, as a synergistic agent with checkpoint inhibitors in metastatic melanoma, and as an inhaled therapy to restore macrophage function in autoimmune pulmonary alveolar proteinosis.
How does inhaled sargramostim differ from injected forms?
Inhaled sargramostim is delivered directly to the airways, targeting alveolar macrophages to improve surfactant clearance in aPAP. Injected forms act systemically, stimulating circulating myeloid cells and enhancing broader immune responses such as vaccine adjuvancy.
Are there any serious side effects I should be aware of?
In the reported trials, sargramostim did not cause serious adverse events. Common, usually mild effects include fever, injection‑site redness, and bone pain. Rare hypersensitivity reactions can occur, particularly with the yeast‑derived product, so patients are monitored during treatment.
Is sargramostim approved for cancer treatment?
Sargramostim is not approved as a cancer therapy. Its use in glioblastoma vaccine protocols and melanoma checkpoint‑inhibitor combinations is investigational and limited to clinical study settings.
Can sargramostim be used at home?
Because sargramostim is a prescription biologic administered by injection or inhalation, it should be prescribed and supervised by a qualified healthcare professional. Home administration may be possible under medical guidance, but the drug is not intended for unsupervised use.
What is Sargramostim?
Sargramostim is a prescription‑only, recombinant human granulocyte‑macrophage colony‑stimulating factor (GM‑CSF) belonging to the colony‑stimulating factor family. It is administered by injection (intravenous or subcutaneous) and, in an inhaled formulation, directly to the lungs. The protein stimulates myeloid cells and is being explored as an immune adjuvant in cancer vaccines, as a synergist with checkpoint inhibitors for melanoma, and as a disease‑modifying therapy for autoimmune pulmonary alveolar proteinosis (aPAP).
What is Sargramostim used for?
Sargramostim is educationally associated with: Treatment of acute radiation syndrome (ARS), Neutrophil recovery in AML induction chemotherapy, Accelerate neutrophil recovery, Graft failure or engraftment delay, Treat pulmonary alveolar proteinosis, Mobilization of hematopoietic progenitor cells, Accelerate myeloid recovery after bone marrow transplantation, Immunomodulation in COVID-19 (investigational). Educational only — not medical advice.
How is Sargramostim administered?
Recorded routes of administration: Inhalation, Intravenous, Subcutaneous.
What are the potential side effects of Sargramostim?
Reported adverse effects include: Bone pain, Fever and constitutional symptoms, Fluid retention / peripheral edema, Injection site reactions, Capillary leak syndrome, First-dose reaction (flushing, hypotension, tachycardia, dyspnea), Fever, Injection site reaction. This list is not exhaustive — consult a qualified clinician.
Who should avoid Sargramostim?
Recorded contraindications: Hypersensitivity to sargramostim or yeast proteins, Hypersensitivity to sargramostim, yeast-derived products, or any component, Active systemic infection without adequate antimicrobial coverage, Neonates (benzyl alcohol-containing formulation), Concurrent use with chemotherapy or radiotherapy, Excessive leukemic myeloid blasts in bone marrow or peripheral blood (≥10%). Consult a qualified clinician before use.